Director/PDMR Shareholding

Bioventix plc ("Bioventix" or the "Company") Director dealing Bioventix plc (AIM: BVXP) was notified on 29 April 2015 that on the same day,due to institutional investor demand, Peter Harrison, Chief Executive of theCompany, sold 53,000 ordinary shares of 5 pence each ("Ordinary Shares") in theCompany at a price of 800 pence per Ordinary Share (the "Sale"). Following theSale, Mr Harrison holds 608,176 Ordinary Shares, representing 12.0% of theissued share capital of the Company. Mr Harrison and associated persons have agreed not to dispose of any additionalOrdinary Shares for a period of 12 months. For further information please contact: Bioventix plcPeter Harrison Chief Executive Officer Tel: 01252 728 001 finnCap Ltd Tel: 020 7220 0500Geoff Nash/Simon Hicks Corporate FinanceSteve Norcross Corporate Broking About Bioventix plc: Bioventix (www.bioventix.com) specialises in the development and commercialsupply of high-affinity monoclonal antibodies with a primary focus on theirapplication in clinical diagnostics, such as in automated immunoassays used inblood testing. The antibodies created at Bioventix are generated in sheep andare of particular benefit where the target is present at low concentration andwhere conventional monoclonal or polyclonal antibodies have failed to produce asuitable reagent. Bioventix currently offers a portfolio of antibodies tocustomers for both commercial use and R&D purposes, for the diagnosis ormonitoring of a broad range of conditions, including heart disease, cancer,fertility, thyroid function and drug abuse. Bioventix currently suppliesantibody products and services to the majority of multinational clinicaldiagnostics companies. Bioventix is based in Farnham, UK and its shares aretraded on AIM under the symbol BVXP.